Minimal residual disease (MRD) monitoring via quantitative PCR (qPCR) detection of Ag receptor gene rearrangements has been the most sensitive method for predicting prognosis and making post-transplant treatment decisions for patients with ALL. Despite the broad clinical usefulness and standardization of this method, we and others have repeatedly reported the possibility of false-positive MRD results caused by massive B-lymphocyte regeneration after stem cell transplantation (SCT). Next-generation sequencing (NGS) enables precise and sensitive detection of multiple Ag receptor rearrangements, thus providing a more specific readout compared to qPCR. We investigated two cohorts of children with ALL who underwent SCT (30 patients and 228 samples). The first cohort consisted of 17 patients who remained in long-term CR after SCT despite having low MRD positivity ( o0.01%) at least once during post-SCT monitoring using qPCR. Only one of 27 qPCR-positive samples was confirmed to be positive by NGS. Conversely, 10 of 15 samples with low qPCR-detected MRD positivity from 13 patients who subsequently relapsed were also confirmed to be positive by NGS (P = 0.002). These data show that NGS has a better specificity in post-SCT ALL management and indicate that treatment interventions aimed at reverting impending relapse should not be based on qPCR only.
INTRODUCTION
During the last two decades, minimal residual disease (MRD) testing has become a crucial part of modern treatment for ALL. Since 2000, quantitative PCR (qPCR) for clonal Ig and TCR gene rearrangements has been thoroughly standardized via international collaboration and used for treatment decisions in several leading treatment protocols for both childhood and adult ALL. [1] [2] [3] [4] High MRD values before allogeneic stem cell transplantation (SCT) have been shown to be a clear marker of poor prognosis posttransplant, [5] [6] [7] [8] [9] [10] [11] and regular post-transplant MRD monitoring using sensitive techniques has become a prerequisite for early treatment interventions in cases of MRD positivity, for example, immunosuppression withdrawal, donor-lymphocyte infusions or further chemotherapy. 11, 12 The Ag receptor-based qPCR method requires defining clonal V-(D)-J rearrangement of Ig/TCR in a diagnostic or relapse sample, designing patient-specific primers and optimizing patient-specific qPCR assays. 13 This approach enables MRD monitoring in most patients but has some technical and biological pitfalls that need to be considered when interpreting the data.
The clone-specific qPCR primers may also amplify comparable sequences in physiological B or T lymphocytes. This phenomenon was discovered during multiple rounds of international quality controls via adding physiological controls to each experiment. Strict rules were set for defining MRD positivity in cases where therapy intensification is based on low-positive MRD results (for example, donor lymphocyte infusion (DLI) after SCT).
14 A study performed by van der Velden et al. 15 showed that if these strict criteria are applied (the CT value of at least one of the three replicates is ⩾ 3.0 CT lower than the lowest CT of background), an unspecific amplification would represent a minor problem on the front-line ALL treatment protocol. However, we repeatedly observed weak (positive, not quantifiable) post-transplant MRD positivity in patients with ALL whose MRD results were negative in subsequent evaluations, in patients who stayed in long-term CR. We demonstrated that these low-level positive results were, with high probability, false because they mainly occurred at time points with massive B-lymphocyte regeneration (day 180, 1 or 2 years after SCT) in samples that also showed weak 'cross-positive' qPCR results when deliberately investigated by assays designed for other patients. Moreover, the size of these qPCR products frequently differed from the expected size. 16 Based on these findings, we have re-evaluated the size of positive, non-quantifiable PCR products in patients post-SCT and have ruled out MRD positivity in 30-40% of these cases. In the remaining cases, we usually repeated the examination after approximately 1 month to prevent treatment intervention based on potentially false-positive MRD results.
Recently, next-generation sequencing (NGS) has provided an unprecedented possibility of detecting the sequences of all possible Ig/TCR rearrangements in the sample, derived from both the leukemic and normal cells. [17] [18] [19] In a study of front-line treatment for ALL, 18 we previously showed that NGS had a sensitivity similar to that of qPCR when a similar amount of DNA was used and that the relapse prediction based on day 33 MRD suggested that NGS had better specificity. Thus, we wanted to re-evaluate the samples with weak qPCR-detected MRD positivity using the novel NGS-based method. For NGS re-evaluation, we chose samples from patients from two independent EuroMRD centers who stayed in CR despite low MRD positivity post-SCT. Low-positive samples from patients who underwent relapse after SCT were investigated as controls. We showed that NGS positivity is far more accurate for relapse prediction than qPCR positivity and that a substantial portion of positive, not quantifiable post-SCT results was most likely false positives.
SUBJECTS AND METHODS Patients
Patients were recruited from two EuroMRD group centers (Prague and Rotterdam) based on the following eligibility criteria: (1) a DNA sample was available, (2) patients did not relapse and remained in CR for a follow-up period of at least 2 years and (3) qPCR MRD result was positive, not quantifiable, and fulfilled the EuroMRD criteria for therapy intensification for at least one time point by at least one Ig/TCR target. The MRD result was declared positive if the CT value of at least one of the three replicates was ⩾ 3.0 CT lower than the lowest CT of background (polyclonal DNA from healthy donors 14 ) . Seventeen patients in continuous complete remission, with at least a 2-year follow-up (median, 10.4 years; range, 2.2-15.8), matched the eligibility criteria. As a control group, 13 patients who had at least one low-positive MRD time point and who subsequently relapsed post-SCT were selected.
A total of 30 children with ALL (aged 1-18 years, 28 = B-ALL, 2 = T-ALL) who underwent SCT between 2000 and 2014 were evaluated. In total, 228 bone marrow (BM) or peripheral blood (PB) DNA samples were investigated by qPCR, and 42 samples were re-evaluated by NGS. The qPCR MRD follow-up of a portion of the patients was already reported in previous studies. 12, 16 Hematopoietic stem cell transplantation
The patients were transplanted due to relapsed or high-risk ALL in their first (13), second (13) or third (4) remission. Donors of hematopoietic stem cells were HLA-identical siblings in four cases and unrelated donors from BMT registries in 26 cases. BM was transplanted in 19 cases; PBSC, in nine cases; and umbilical cord blood, in two cases. Pre-transplant conditioning with TBI at a dose of 12 Gy and etoposide of 60 mg/kg was used in the majority of patients (n = 20), and busulfan-based conditioning (7 × busulfan, cyclophosphamide and melphalan; 2 × busulfan, cyclophosphamide and etoposide; and 1 × busulfan and fludarabine) was used in 10 children. In the majority of unrelated donor transplants (n = 25), rabbit anti-thymocyte globulin was used. GvHD prophylaxis consisted of cyclosporin A (CsA) in HLA-identical sibling transplants and of CsA (n = 2) or a combination of CsA and methotrexate (n = 19), CsA and methylprednisolone (n = 4) or CsA and mycophenolate mofetil (n = 1) in unrelated donor transplants.
Detection of residual disease by qPCR
Mononuclear cells from the BM or PB samples were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density centrifugation and stored as dry pellets. Genomic DNA was isolated using a QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany). Primers and protocols for the detection of Ig heavy chain (IGH) rearrangements, Ig light chain kappa deletions, T-cell receptor gamma and T-cell receptor delta gene rearrangements, and TAL1 deletions have been described previously. 20, 21 Clonality of PCR products was confirmed by heteroduplex analysis. GenBank using the ImMunoGeneTics Database (http://www.imgt.org/, IMGT, European Bioinformatics Institute, Montpellier, France). Patientspecific forward primers for RQ-PCR were designed using the VECTOR NTI 8 Suite Software (Thermo Fisher) or Primer Express (Applied Biosystems, Foster City, CA, USA) and OLIGO 6.0 software (Molecular Biology Insights, Inc., Cascade, CO, USA). Family specific reverse primers and probes for IGH, immunoglobulin kappa chain, T-cell receptor delta and T-cell receptor gamma have been described previously. [22] [23] [24] [25] Ig/TCR RQ-PCR was performed on TaqMan 7500 (Thermo Fisher) or StepOne Plus (Applied Biosystems). Standard curves were prepared by diluting the diagnostic samples in pooled polyclonal DNA from the PB of at least five healthy donors, which was also used as a negative control. Using patient-specific systems, MRD was measured in triplicate, with 250-600 ng of DNA per reaction. Quantification of the albumin gene was used to normalize the DNA concentration and quality. 26 The current EuroMRD criteria for RQ-PCR sensitivity, quantitative range and MRD interpretation were used. 14 The sensitivity was at least 10 − 4 for all used assays. The fusion gene transcripts were detected as described previously.
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Detection of residual disease by NGS
Detection of MRD was performed as described previously. 18 In brief, the sequencing libraries were created using 500 ng of DNA in a two-step PCR using modified BIOMED-2 primers for IGH 21 and an in-house set of primers for detecting virtually all TCR gamma rearrangements. 29 The primers for incomplete IGH rearrangements were derived from primers presented by Szczepanski et al. 30 The primers for incomplete IGH multiplex detection are shown in Supplementary Table 1 . The design of the primers enabled the amplification of all rearranged segments tested by qPCR. Unlike the method described in a previous study, 18 we did not add polyclonal DNA to prevent MRD overestimation in samples with possible B-cell aplasia because we only aimed to discern MRD positivity versus negativity. The sensitivity of the T-cell receptor gamma assay was tested using NGS for dilutions of diagnostic samples from patients with ALL with clonal combinations of respective V and J segments and reached at least 10
for all tested combinations. The sequencing of samples from patients with a negative NGS-MRD result was performed with a minimum coverage of 414 567 reads of corresponding size (range 414 567-4 236 212, median 1 051 484) on Ion Torrent or Ion Proton instruments using Hi-Q chemistry (Thermo Fisher). In samples with a positive NGS-MRD result, lower coverage was accepted without the need to repeat the sequencing. MRD assessment was performed as described previously. 18 The results were double-checked using a fixed 40 bp window chosen by a researcher experienced in V-(D)-J sequence biology to optimally cover the hypervariable V-(D)-J region, with MRD positivity defined as matching the diagnostic/relapse sequence with a maximum of 2 bp mismatches in rearrangements harboring 2N-regions (IGH) and a maximum of 1 bp mismatch in rearrangements harboring 1N-region (T-cell receptor gamma and incomplete IGH) in a 40 bp window and the same V and J segments. The similarity of the matching reads identified by this approach with the leukemia-specific sequence from diagnosis was re-checked manually for the V-and J-segment match in the remaining portion of the sequence.
RESULTS
Patients who stayed in CR despite low MRD positivity post-SCT We investigated post-SCT samples from 17 patients who remained leukemia free for at least 2 years post-SCT (median, 10.4 years; range, 2.2-15.8). All patients had at least one positive MRD result by qPCR using strict EuroMRD criteria that were set to define MRD positivity in cases of therapy intensification; in total, there were 33 qPCR-positive samples (Figure 1 , full or half-full circles in cases where both or only one Ig/TCR target were positive). We suspected that most of these weakly positive results were false positive due to massive lymphocyte regeneration at the respective time points. We re-evaluated 27 of these samples with available DNA by NGS targeted to Ig or TCR targets with qPCR-positive results. All but one sample were negative as detected by NGS (Figure 1, empty squares) . Only samples from patient #2065 was determined to be positive by both qPCR and NGS as early as 30 days post-SCT (day +30).
We were already aware of possible false-positive qPCR results at the time of MRD monitoring based on the findings summarized in our previous study. 16 Moreover, all patients had low or negative MRD before SCT and therefore a lower risk of relapse. Additionally, parallel testing in six patients with available fusion genes (BCR/ABL1, ETV6/RUNX1, KMT2A/MLLT3, KMT2A/MLLT10 and KMT2A/MLLT1) revealed negative results. Therefore, no treatment interventions based on MRD were conducted in most patients.
Patient #375 (BCR/ABL1-positive), who had qPCR positivity/NGS negativity at day +115 received prophylactic Glivec since day +60 based on a low-positive qPCR result in PB (sample not tested by NGS).
Patient #598 (KMT2A/MLLT3-positive) had the first positive MRD result at day +90 post-SCT. All three replicates were positive within the quantitative range (10 − 4 ) of the experiment, but the distance between Ct values of replicates was higher than 1.5. Consequently, despite the relatively high MRD levels, this sample had to be expressed as 'positive, not quantifiable' according to EuroMRD criteria. 14 The CsA was stopped based on MRD positivity, and because the next BM evaluations were also positive, four DLIs were applied. The patient remained in CR at the 12-year follow-up with weak qPCR MRD positivity until 4 years post-SCT. Retrospectively, MRD detection via the KMT2A/MLLT3 fusion gene was negative, and the NGS re-evaluation of three samples with qPCR positivity were negative.
Patients with low-positive MRD post-SCT who subsequently relapsed We re-evaluated MRD in 13 patients who subsequently relapsed as a control group. Most patients from this group had MRD values higher than 10 − 4 before the transplant (range, negative to 5 × 10 − 2 ; median, 9 × 10 − 4 ) and therefore, by definition, had a higher risk of relapse. Moreover, the MRD pattern of positive results differed from that of the non-relapsing group (repeated positivity in subsequent evaluations and positivity in both qPCR targets). Therefore, various treatment interventions were applied in this cohort of 13 patients, for example, immunosuppression tapering, DLI, Glivec administration or a protocol consisting of cyclosporin A withdrawal at day +36 and repeated DLIs post-transplant in Dutch patients 12 ( Figure 1b ). Based on sample availability and low MRD positivity by qPCR, we selected 15 samples from the post-SCT follow-up of these patients for NGS re-evaluation. Ten of 15 samples were also positive as detected by NGS, which is significantly different from the non-relapse group (1 of 27 vs 10 of 15, P = 0.002). In two patients (#587 and #825), qPCR levels were positive, while NGS, KMT2A/MLLT10 or BCR/ABL1 MRD levels were negative, thus raising the possibility that false positivity of Ig/TCR qPCR can also occur in patients who subsequently relapse.
The cause of putative qPCR false positivity In our previous study, we stated that massive post-transplant B-lymphocyte regeneration is most likely the major reason for unspecific primer binding to similar V-(D)-J sequences in the sample, thus leading to false qPCR-detected MRD positivity. 16 NGS provided a unique opportunity to determine whether this hypothesis was true. We used the sequences of primers used for qPCR in individual patients from the current study to look for a possible match in all samples investigated by NGS. For all but one of the primers, the stretches of nucleotides matching the primer sequences with a maximum of 2 bp mismatches were present in fastq files from different patients, thus likely explaining the possibility of non-specific amplification due to random annealing of primers to places with high sequence similarity ( Figure 2) . We assessed whether the length of the qPCR primer could affect the extent of non-specific amplification by checking the size of the primers with NGS-negative/qPCR-positive results. The length of the primers (17-29 bp, median 23 bp) was within a normal range and did not differ from other oligonucleotides.
DISCUSSION
Despite its limitations and technical demands, qPCR for clonal Ag receptor rearrangements has proven to be a highly useful and sensitive tool for monitoring MRD during the last 15 years. This method has been thoroughly standardized (within the EuroMRD Group; www.EuroMRD.org) and has enabled precise prognostication in front-line, relapse and transplant treatment management. However, others and we have been aware of the possible limits of this method and repeatedly noticed supposedly false-positive results, which might lead to overtreatment during the posttransplant period. In a consensus recommendation of European ALL study groups, low-level, non-quantifiable MRD positivity was judged as a sort of gray area and, therefore, should be valued within the respective protocols considering the treatment strategy and the respective time point, for example, as a warning signal in post-remission monitoring. 31 Now, with the newly emerging NGS techniques, we showed that these qPCR results had a high probability of being false positive. We could only re-evaluate some of the samples (42 of 60) by NGS. Most samples of patients who did not relapse despite no treatment intervention were concluded to be MRD negative, while the majority of low-positivity samples from patients who relapsed after SCT were confirmed to be MRD-positive by NGS as well.
An alternative explanation would be that qPCR is still more sensitive than NGS and detects the real residual leukemic cells that are under long-term suppression by the graft-versus-leukemia effect. Currently, the NGS approach is usually presented as the most sensitive one, with the number of reads being the main scalable factor influencing the sensitivity of MRD detection. In reality, the main factors influencing this sensitivity are the amount of DNA used for library preparation and the proportional efficiency of multiplex PCR. In our previous study 18 comparing NGS and qPCR in 210 ALL samples, we showed that the sensitivity of both methods was similar, with most differences in the 'gray zone' of weak positives below 10
. The discrepancies in the low-positivity samples were shown to affect the relapse prediction based on day +33 MRD positivity, which was more accurate using NGS. Additionally, the different sizes of the qPCR products that were observed in a substantial part of the low-positive samples in our routinely evaluated patients (data not shown) points toward the false positivity of qPCR. 16 Alternatively, the relatively high number of putatively false-positive qPCR samples could be explained by an incorrect interpretation of qPCR data and non-adherence to guidelines for MRD positivity definition in situations with possible therapy intensification. We re-interpreted all qPCR runs according to current criteria (published in 2007). Both centers that performed qPCR in this study were among the founding members of the EuroMRD (former name, ESG-MRD-ALL) Group, participated in writing guidelines for data interpretation, 14 and have successfully undergone multiple rounds of international quality control. Therefore, inappropriate interpretation of the qPCR data is highly unlikely.
We suppose that similar weak false-positive qPCR samples after SCT may also exist (with possible treatment consequences) in other centers. This possibility is suggested by a study exploring post-transplant MRD monitoring in the largest cohort of children with ALL at this time. 11 Although all but one of the patients with MRD higher than or equal to 10 − 4 during the first year of post-transplant monitoring had a subsequent event, only approximately half of the patients with low MRD values (o 10 − 4 ) at various time points during the first year post-SCT had an event. For example, patients with low MRD positivity at day +180 had a very good 3-year EFS of 64 ± 13%. 11 Yet another issue that might theoretically artificially influence the results is the composition of the groups of relapsing and non-relapsing patients. Clearly, the patients with subsequent relapse tend to have two positive targets rather than one, more consecutive MRD-positive samples and more frequent positivity in the complementary MRD target in the same sampling time point. In fact, this diversity only supports our notion that there is a relatively sharp difference between the two groups of post-SCT patients: those with a real persisting MRD burden and a high risk of relapse and those with randomly emerging, most likely false, MRD positivity who sustain CR. There were several patients in the relapsing group for whom positivity (even quantifiable) was temporarily followed by negative samples. This result could be caused either by technical factors (aplastic samples, PB contamination) or by administered treatment (imatinib and/or DLI). We favor the second option because in most cases the change to negativity occurred relatively late after the transplant and coincided with treatment.
The impact of post-transplant MRD assessed via NGS has been evaluated in the study by Children's Oncology Group. Pulsipher et al. 19 examined post-transplant NGS-MRD in 53 patients with at least one post-transplant sample available. The post-transplant outcome was shown to be related to any MRD positivity post-SCT, irrespective of the time point (Table 2) . 19 Compared to 5 relapses in the 38 patients with negative post-transplant MRD, out of 15 patients with at least 1 positive sample, 11 relapsed. If we had analyzed our data in the same way, we would have observed 10 relapses in 11 patients with at least 1 NGS-positive result compared to 3 relapses in 19 patients with NGS negativity. Although we acknowledge the difference in treatment protocols, which could skew the MRD significance, our data are consistent with the previous study and further confirm the specificity of NGS-MRD for relapse prediction. The positivity in the patients who did not relapse despite NGS-MRD positivity can be explained by the graft-versus-leukemia effect achieved early post transplant, when the graft still has not obtained tolerance, as exemplified in patient no. 2065.
In summary, our data support the working hypothesis that NGS is a significantly more specific tool for relapse prediction in posttransplant management of ALL. The protocols and guidelines for NGS data interpretation are currently being finalized within the EuroClonality-NGS consortium (chairman: Dr A Langerak), and we believe that NGS will replace qPCR in the near future. However, declaring NGS a method of choice for post-transplant MRD will be challenging due to the costs and logistics of NGS monitoring. The economics and turnaround time of NGS depend on the number of investigated samples and only surpass qPCR if samples of several patients can be batched in one run. Thus, NGS might slow down the reporting of MRD results in low-throughput laboratories that can deliver qPCR results within 1 or 2 days but have to wait for sufficient sample numbers for cost-effective NGS-based MRD assessment. On the other hand, the time and costs needed for qPCR optimization are not needed for NGS, and turnaround time is substantially lower with more multiplexed samples because contrary to qPCR the primers and protocols are identical for different patients. The choice of the method will depend on the development of NGS pricing and on the availability of suitable small-scale sequencers. Thus, qPCR will still be used by many centers in the near future. Based on the findings of this and our previous study, 16 we strongly recommend interpreting samples with low (positive, not quantifiable) qPCR positivity after SCT with great caution, especially in patients who already had low MRD levels before transplant and those who only have a positive result for one of two Ig/TCR targets. Based on our experience, in 30-40% of such cases, the positivity can be excluded due to the different size of the qPCR product. In the same line, in patients with a negative complementary MRD target (typically a fusion gene targeted at either the cDNA or genomic DNA level), prognostic considerations leading to therapy intensification must be prudent. An attempt should be made to redefine the low MRD positivity post SCT, which would justify treatment intervention. All patients with at least one quantifiable qPCR result relapsed, which supports the prognostic strength of high MRD shown in previous reports. However, limiting therapeutic intervention only to this group could jeopardize the treatment. Balduzzi et al. 10 showed that all patients with MRD higher than 10 − 3 post SCT ultimately relapsed, regardless of immunosuppression discontinuation or donorlymphocyte infusion. A useful addition to the current workflow could be re-evaluating all low-positive qPCR products on a chip electrophoresis (Agilent or similar), as this approach helps to eliminate a significant portion of the false-positive results. 16 Another option could be acting only if two low-positive markers are detected. This cannot be used in patients with only one marker, but this situation is rare and should not be a major False-positive post-SCT qPCR results identified by NGSproblem. In our study, only 2 of the 11 patients who were positive in only one of the three PCR replicates relapsed, compared to 11 of the 19 patients with higher MRD positivity at any time point. Thus, samples with such low positivity might be omitted and treatment interventions could be applied only in cases of repeated positivity or an increase in MRD levels. However, a broader discussion based on collected low-positive data from different treatment protocols is necessary to solve the problem of how to correctly interpret positivity below the quantitative range.
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